Protect Animal Health and DotBio Announce Collaboration to Develop Advanced Therapies and Technologies for Canine and Feline Health

On July 29, Protect Animal Health (PAH) and DotBio announced a strategic collaboration to develop innovative therapeutic antibody discovery platform technologies and a therapeutic antibody pipeline specifically tailored for dogs and cats. This partnership aims to address the unmet medical needs of pets, providing advanced treatments and improving the quality of life for companion animals worldwide.

Advancing Veterinary Medicine With an Integrated Therapeutic Antibody Discovery Platform

With a shared commitment to advancing veterinary medicine, PAH and DotBio are combining their expertise to create a fully integrated therapeutic antibody discovery platform. This platform will leverage DotBio’s technologies and proprietary methodologies to identify and develop novel therapeutic antibodies targeting a range of diseases prevalent in canine and feline populations.

This partnership shows a dedication to improving pet healthcare and delivering new, effective treatments for a variety of conditions affecting animals. “At PAH, our mission has always been to enhance the health and well-being of pets. This collaboration with DotBio represents a significant step forward in achieving that goal,” expressed CEO of PAH, Haolin Sung. “By combining our extensive knowledge in veterinary medicine with DotBio’s expertise in antibody discovery and engineering, we are poised to make groundbreaking advancements in the treatment of diseases that affect our beloved pets.”

DotBio and PAH teams celebrate their new partnership following the contract signing.

DOTBODY Technology to Ensure Effective Treatments for Chronic Conditions

DotBio will drive therapeutic solutions by using its proprietary modular humanized and stabilized domain antibody technology platform (DOTBODY TECHNOLOGY) and its intracellular antibody technology platform. This collaboration will rapidly identify and optimize high-affinity antibodies, ensuring effective and safe treatments for autoimmune diseases, cancers, and chronic inflammatory disorders.

This partnership is set to bring pets up to speed with the latest treatments and dramatically improve their care. “Pet therapies are three decades behind those available for humans. We are thrilled to partner with PAH to revolutionize the treatment options available for our furry friends,” said Ignacio Asial, Founder and CEO of DotBio. “Together, we aim to address the pressing medical needs of dogs and cats, bringing to pets the state-of-the-art therapeutic solutions currently available only to humans, such as multispecific antibodies and immuno-modulatory therapies.”

Taiwan’s Vice President Presents Protect the Outstanding New Startup Award

Taiwan’s Vice President, Hsiao Bi-khim, presented the 2024 Taiwan BIO Awards at the BIO Asia-Taiwan event. The Taiwan Bio Industry Organisation (TBIO) recognized 19 institutions and product technologies across four categories: the “Industry Gold Award,” “Potential Benchmark Award,” “Outstanding New Startup Award,” and “Annual Industry Innovation Award.” These accolades celebrated exceptional biotech achievements, highlighting Taiwan’s growth and global potential.

Protect Animal Health’s Chief Research and Development Officer, Pearl Fong, presents the latest findings on the company’s pet care and animal health technology.

Protect received the “Outstanding New Startup Award” for its innovative cancer immunotherapy vaccines for pets, addressing aging-related health issues in animals. The company, focused on developing new immune therapies for companion animals, utilizes a “dual immune checkpoint” design targeting PD-1 and CTLA-4 pathways to enhance immune response. Their lead product, PT001, a fusion protein in early clinical trials, aims to treat various diseases, including tumors. CEO Haolin Sung emphasized the company’s commitment to creating first-in-class and best-in-class products, attracting global attention and major partnerships.

In addition to PT001, Protect develops PT101 to target a broader range of diseases, including cancer, cardiovascular disease, and infections. The company has won over 30 innovation and technology awards, showcasing its strength in biotech. Focusing on research and maintaining a clear development direction, Protect aims to expand its product line and lead in both human and animal health.

Protect Animal Health CEO, Haolin Sung (center right), receives the Outstanding New Startup Award from Taiwan’s Vice President, Hsiao Bi-khim (center left), at the BIO Asia-Taiwan 2024.

About PAH

Protect Animal Health is a Taiwanese life science development company specializing in companion animal care, dedicated to making advanced therapies accessible for pets, driving the change for the outdated animal health landscape. Beyond oncology drugs, Protect Animal Health utilizes human drug development expertise to tackle unmet needs in all high-potential disease areas in pets, also acting as an incubator of valuable companion animal drug pipelines.

About DotBio

DotBio, a Singapore-incorporated biopharmaceutical R&D company, specializes in next-generation antibody therapies. It utilizes a proprietary humanized, stable Domain Therapeutic Antibody (“DotBody”) platform technology that simplifies generating multi-specific therapies. The company possesses proprietary DotBody libraries and phage display libraries, a directed evolution and stabilization Colony Filtration (“CoFi”) technology, numerous target-specific Dot antibody modules, and various preclinical assets in the immuno-oncology field. Consequently, it leads advancements in therapeutic development.

Author

Bernice Lottering